title: Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia.
authors.affiliation: Università Vita-Salute San Raffaele, Milan, Italy.|IRCCS Istituto Scientifico San Raffaele, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Ghia
authors.affiliation: Università Vita-Salute San Raffaele, Milan, Italy.|IRCCS Istituto Scientifico San Raffaele, Milan, Italy.
authors.forename: Lydia
authors.initials: L
authors.lastname: Scarfò
authors.affiliation: Merck & Company, Incorporated, Kenilworth, NJ; and.
authors.forename: Susan
authors.initials: S
authors.lastname: Perez
authors.affiliation: Merck & Company, Incorporated, Kenilworth, NJ; and.
authors.forename: Kumudu
authors.initials: K
authors.lastname: Pathiraja
authors.affiliation: Merck & Company, Incorporated, Kenilworth, NJ; and.
authors.forename: Martha
authors.initials: M
authors.lastname: Derosier
authors.affiliation: Merck & Company, Incorporated, Kenilworth, NJ; and.
authors.forename: Karen
authors.initials: K
authors.lastname: Small
authors.affiliation: Merck & Company, Incorporated, Kenilworth, NJ; and.
authors.forename: Christine
authors.initials: C
authors.lastname: McCrary Sisk
authors.affiliation: Auckland City Hospital, Auckland, New Zealand.
authors.forename: Nigel
authors.initials: N
authors.lastname: Patton
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage* / Q000009:adverse effects; D003497:Cyclic N-Oxides; D005260:Female; D006801:Humans; D007212:Indolizines; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011726:Pyridinium Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003497:Cyclic N-Oxides; D007212:Indolizines; D011726:Pyridinium Compounds; C553669:dinaciclib; C527517:ofatumumab